Iovance Biotherapeutics Submits EU Marketing Application for Lifileucel in Advanced Melanoma
Iovance Biotherapeutics, Inc. submitted a marketing authorization application (MAA) to the European Medicines Agency (EMA) for lifileucel, a tumor-innfiltrating lymphocyte (TIL) therapy, for the treatment of adult patients with unresectable or metastatic melanoma previously treated with a PD-1 blocking antibody, and if BRAF V600 mutation positive, a BRAF inhibitor with or without a MEK inhibitor […]